Skip to main content
Signal8
Launch Terminal

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Ascentage Pharma Group International logo

Ascentage Pharma Group International

NASDAQ:AAPGHealthcare
-2.85%$14.46
Mkt Cap$1.35B
Float5.17M
O/S93.39M
Vol
$ Vol
RVOL
Inst Own0.0%
SI0.3%
Earnings
Dilution
Ascentage Pharma Group International logoNASDAQ:AAPG$14.46-2.85%
Phase Distribution
53 lead-sponsored trials·26 active·9 completed
Early Phase 11
Phase 122
Phase 1/216
Phase 26
Phase 37
Not applicable1
(6 more as collaborator)
Status Overview
Recruiting23
Active, not recruiting3
Completed9
Stopped7
Expanded access1
Unknown10

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Recruiting

    A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

    Olverembatinib, Investigator's choice of TKI

    Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

    Enrollment
    350
    Start
    Aug 2023
    Primary Completion
    Dec 2027est.
    Completion
    Jun 2029est.
    NCT06051409
  • Phase 3
    Recruiting

    Global Trial in APG2575 for Patients With CLL/SLL

    lisaftoclax +BTK inhibitor, BTK inhibitor

    CLL/SLL

    Enrollment
    400
    Start
    Dec 2023
    Primary Completion
    Dec 2026est.
    Completion
    Oct 2027est.
    NCT06104566
  • Phase 3
    Recruiting

    A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

    Lisaftoclax (APG-2575), Acalabrutinib

    CLL/SLL

    Enrollment
    344
    Start
    Apr 2024
    Primary Completion
    Aug 2027est.
    Completion
    Aug 2028est.
    NCT06319456
  • Phase 3
    Recruiting

    A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

    APG-2575(Lisaftoclax ), Azacitidine Injection

    Acute Myeloid Leukemia

    Enrollment
    486
    Start
    Jun 2024
    Primary Completion
    May 2028est.
    Completion
    Mar 2029est.
    NCT06389292
  • Phase 3
    Recruiting

    Study of Olverembatinib (HQP1351) in Patients With CML-CP

    olverembatinib, Bosutinib

    Chronic Myeloid Leukemia, CML +1

    Enrollment
    333
    Start
    Feb 2024
    Primary Completion
    Jun 2027est.
    Completion
    Jul 2028est.
    NCT06423911
  • Phase 3
    Recruiting

    A Study of Olverembatinib in SDH-deficient GIST.

    Olverembatinib

    GIST

    Enrollment
    40
    Start
    Nov 2024
    Primary Completion
    Mar 2027est.
    Completion
    Jun 2029est.
    NCT06640361
  • Phase 3
    Recruiting

    Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

    Lisaftoclax (APG-2575), Azacitidine Injection

    Higher-risk Myelodysplastic Syndrome

    Enrollment
    490
    Start
    Jan 2025
    Primary Completion
    Jun 2029est.
    Completion
    Dec 2029est.
    NCT06641414
  • Phase 2
    Unknown status

    A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation

    HQP1351

    Chronic Myeloid Leukemia, Chronic Phase

    Enrollment
    41
    Start
    Apr 2019
    Primary Completion
    May 2024est.
    Completion
    Feb 2025est.
    NCT03883087
  • Phase 2
    Unknown status

    A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

    HQP1351

    Chronic Myeloid Leukemia - Accelerated Phase

    Enrollment
    23
    Start
    Apr 2019
    Primary Completion
    Apr 2024est.
    Completion
    Mar 2025est.
    NCT03883100
  • Phase 2
    Completed

    A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

    HQP1351, Hydroxyurea or Interferon-based therapy

    Chronic Myeloid Leukemia, Chronic Phase

    Enrollment
    144
    Start
    Oct 2019
    Primary Completion
    Aug 2024
    Completion
    Aug 2024
    NCT04126681
  • Phase 2
    Recruiting

    A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

    APG-115, APG-2575

    T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma

    Enrollment
    78
    Start
    Jul 2021
    Primary Completion
    May 2026est.
    Completion
    May 2027est.
    NCT04496349
  • Phase 2
    Unknown status

    A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B

    APG-1387, Entecavir 0.5 mg

    Hepatitis B, Chronic Hep B +1

    Enrollment
    122
    Start
    Jun 2020
    Primary Completion
    Oct 2022est.
    Completion
    Oct 2025est.
    NCT04568265
  • Phase 2
    Recruiting

    Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

    APG2575

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

    Enrollment
    75
    Start
    Dec 2021
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2027est.
    NCT05147467
  • Phase 1/2
    Active, not recruiting

    A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

    Phase 1b: APG-115+pembrolizumab

    Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma +6

    Enrollment
    230
    Start
    Aug 2018
    Primary Completion
    Dec 2025est.
    Completion
    Dec 2025est.
    NCT03611868
  • Phase 1/2
    Terminated

    Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

    APG-1252, Paclitaxel

    Small Cell Lung Cancer

    Enrollment
    28
    Start
    Aug 2020
    Primary Completion
    Aug 2021
    Completion
    May 2022
    NCT04210037
  • Phase 1/2
    Terminated

    Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

    APG-1387 for Injection, Toripalimab

    Advanced Solid Tumor

    Enrollment
    40
    Start
    Apr 2020
    Primary Completion
    Nov 2024
    Completion
    Nov 2024
    NCT04284488
  • Phase 1/2
    Withdrawn

    A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

    APG-1252, Ruxolitinib

    Myelofibrosis

    Enrollment
    0
    Start
    Dec 2020est.
    Primary Completion
    Dec 2022est.
    Completion
    Jun 2023est.
    NCT04354727
  • Phase 1/2
    Unknown status

    A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

    APG-115, 5-azacitidine

    AML, Acute Myeloid Leukemia +5

    Enrollment
    69
    Start
    Dec 2020
    Primary Completion
    Dec 2024est.
    Completion
    Dec 2025est.
    NCT04358393
  • Phase 1/2
    Recruiting

    Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

    APG-2575, Rituximab

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

    Enrollment
    123
    Start
    Aug 2020
    Primary Completion
    Oct 2024
    Completion
    Dec 2025est.
    NCT04494503
  • Phase 1/2
    Recruiting

    Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

    Lisaftoclax (APG-2575), Reduced-dose HHT

    Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy

    Enrollment
    682
    Start
    Sep 2020
    Primary Completion
    Sep 2028est.
    Completion
    Sep 2029est.
    NCT04501120
  • Phase 1/2
    Terminated

    APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

    APG-1387 for Injection, Gemcitabine

    Advanced Pancreatic Cancer

    Enrollment
    21
    Start
    Mar 2021
    Primary Completion
    Jun 2024
    Completion
    Dec 2024
    NCT04643405
  • Phase 1/2
    Unknown status

    APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

    APG-2575, Rd

    Multiple Myeloma

    Enrollment
    48
    Start
    Apr 2021
    Primary Completion
    Jan 2024est.
    Completion
    May 2024est.
    NCT04674514
  • Phase 1/2
    Recruiting

    APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

    APG-115, Toripalimab

    Liposarcoma, Advanced Solid Tumor

    Enrollment
    95
    Start
    May 2021
    Primary Completion
    Apr 2026est.
    Completion
    Jan 2027est.
    NCT04785196
  • Phase 1/2
    Unknown status

    APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

    APG-2575+ Pd, APG-2575 + DRd

    Multiple Myeloma, Amyloidosis

    Enrollment
    108
    Start
    Dec 2021
    Primary Completion
    Sep 2024est.
    Completion
    Dec 2024est.
    NCT04942067
  • Phase 1/2
    Suspended

    A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

    APG-2575, Palbociclib

    Breast Cancer, Solid Tumor, Adult

    Enrollment
    65
    Start
    Aug 2021
    Primary Completion
    Aug 2024
    Completion
    Oct 2024est.
    NCT04946864

1-25 of 53

Search ClinicalTrials.gov for “Ascentage Pharma Group International”